Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity
Abstract CD80 is an important co‐stimulatory molecule that participates in the immune response. Soluble CD80 can induce T cell activation and overcome PDL1‐mediated immune suppression. In this study, we aimed to construct recombinant Lactococcus lactis for oral delivery of the soluble CD80 (hsCD80)...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Bioengineering & Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/btm2.10533 |
| _version_ | 1797777254881689600 |
|---|---|
| author | Ziqing Lin Yanqing Tang Zerong Chen Simin Li Xueyan Xu Xufeng Hou Zhenhui Chen Junjie Wen Weisen Zeng Xiaojing Meng Hongying Fan |
| author_facet | Ziqing Lin Yanqing Tang Zerong Chen Simin Li Xueyan Xu Xufeng Hou Zhenhui Chen Junjie Wen Weisen Zeng Xiaojing Meng Hongying Fan |
| author_sort | Ziqing Lin |
| collection | DOAJ |
| description | Abstract CD80 is an important co‐stimulatory molecule that participates in the immune response. Soluble CD80 can induce T cell activation and overcome PDL1‐mediated immune suppression. In this study, we aimed to construct recombinant Lactococcus lactis for oral delivery of the soluble CD80 (hsCD80) protein or the fusion protein containing the cholera toxin B subunit (CTB) and hsCD80 (CTB‐hsCD80) under the control of the nisin‐inducible expression system. The recombinant L. lactis expressed and secreted hsCD80 or CTB‐hsCD80 fusion proteins after induction by nisin in vitro and in the enteric cavity. Additionally, the CTB‐hsCD80 fusion protein showed uptake by intestinal epithelial cells, was cleaved by the furin protease, and was released as free hsCD80 protein into the blood circulation. Orally administered hsCD80 and CTB‐hsCD80 containing L. lactis increased the proportion of activated T cells in the spleen and intestinal epithelium, inhibited tumor growth, and prolonged the survival of tumor‐bearing mice. The hsCD80‐containing L. lactis showed greater therapeutic effects on primary colonic adenoma in APCmin/− mice and completely suppressed tumor growth. Further, recombinant CTB‐hsCD80 in L. lactis was more efficient than hsCD80‐containing bacteria in inhibiting the growth of xenografted colon cancer and melanoma cells. hsCD80 engineered probiotics may serve as a promising new approach for antitumor immunotherapy, especially for colorectal cancer. |
| first_indexed | 2024-03-12T23:01:31Z |
| format | Article |
| id | doaj.art-2dad4ff3d15747f493444fd314b6143a |
| institution | Directory Open Access Journal |
| issn | 2380-6761 |
| language | English |
| last_indexed | 2024-03-12T23:01:31Z |
| publishDate | 2023-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Bioengineering & Translational Medicine |
| spelling | doaj.art-2dad4ff3d15747f493444fd314b6143a2023-07-19T09:59:03ZengWileyBioengineering & Translational Medicine2380-67612023-07-0184n/an/a10.1002/btm2.10533Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunityZiqing Lin0Yanqing Tang1Zerong Chen2Simin Li3Xueyan Xu4Xufeng Hou5Zhenhui Chen6Junjie Wen7Weisen Zeng8Xiaojing Meng9Hongying Fan10Department of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Microbiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health Southern Medical University Guangzhou ChinaGuangzhou Weisengene Biological Technology Co., Ltd. Guangzhou ChinaDepartment of Cell Biology, School of Basic Medicine Southern Medical University Guangzhou ChinaDepartment of Occupational Health and Occupational Medicine, School of Public Health Southern Medical University Guangzhou Guangdong ChinaDepartment of Microbiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health Southern Medical University Guangzhou ChinaAbstract CD80 is an important co‐stimulatory molecule that participates in the immune response. Soluble CD80 can induce T cell activation and overcome PDL1‐mediated immune suppression. In this study, we aimed to construct recombinant Lactococcus lactis for oral delivery of the soluble CD80 (hsCD80) protein or the fusion protein containing the cholera toxin B subunit (CTB) and hsCD80 (CTB‐hsCD80) under the control of the nisin‐inducible expression system. The recombinant L. lactis expressed and secreted hsCD80 or CTB‐hsCD80 fusion proteins after induction by nisin in vitro and in the enteric cavity. Additionally, the CTB‐hsCD80 fusion protein showed uptake by intestinal epithelial cells, was cleaved by the furin protease, and was released as free hsCD80 protein into the blood circulation. Orally administered hsCD80 and CTB‐hsCD80 containing L. lactis increased the proportion of activated T cells in the spleen and intestinal epithelium, inhibited tumor growth, and prolonged the survival of tumor‐bearing mice. The hsCD80‐containing L. lactis showed greater therapeutic effects on primary colonic adenoma in APCmin/− mice and completely suppressed tumor growth. Further, recombinant CTB‐hsCD80 in L. lactis was more efficient than hsCD80‐containing bacteria in inhibiting the growth of xenografted colon cancer and melanoma cells. hsCD80 engineered probiotics may serve as a promising new approach for antitumor immunotherapy, especially for colorectal cancer.https://doi.org/10.1002/btm2.10533cholera toxin B subunit (CTB)human soluble CD80lactic acid bacteriatumor therapy |
| spellingShingle | Ziqing Lin Yanqing Tang Zerong Chen Simin Li Xueyan Xu Xufeng Hou Zhenhui Chen Junjie Wen Weisen Zeng Xiaojing Meng Hongying Fan Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity Bioengineering & Translational Medicine cholera toxin B subunit (CTB) human soluble CD80 lactic acid bacteria tumor therapy |
| title | Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity |
| title_full | Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity |
| title_fullStr | Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity |
| title_full_unstemmed | Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity |
| title_short | Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity |
| title_sort | soluble cd80 oral delivery by recombinant lactococcus suppresses tumor growth by enhancing antitumor immunity |
| topic | cholera toxin B subunit (CTB) human soluble CD80 lactic acid bacteria tumor therapy |
| url | https://doi.org/10.1002/btm2.10533 |
| work_keys_str_mv | AT ziqinglin solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT yanqingtang solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT zerongchen solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT siminli solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT xueyanxu solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT xufenghou solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT zhenhuichen solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT junjiewen solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT weisenzeng solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT xiaojingmeng solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity AT hongyingfan solublecd80oraldeliverybyrecombinantlactococcussuppressestumorgrowthbyenhancingantitumorimmunity |